Wockhardt Share News - Latest Updates, Live News & More

Latest news about Wockhardt

Wockhardt's Zaynich Proves Effective Against Severe Drug-Resistant Infection in U.S. Liver Transplant Patient 8 days ago

Wockhardt Limited's novel antibiotic Zaynich® (Zidebactam/Cefepime, WCK 5222) has successfully treated a severe pan-drug resistant infection in a U.S. liver transplant patient. The case, published in the Journal of Antimicrobial Chemotherapy – AMR, involved a patient with Pseudomonas and Klebsiella infections resistant to all available antibiotics. After a 14-day treatment with Zaynich®, the patient showed significant improvement, with no signs of active infection even six weeks post-treatment. Zaynich® has completed a global Phase III clinical trial and has been used in over 50 patients with highly resistant infections under compassionate use programs.

Wockhardt Ltd Exits US Generics Market, Shifts Focus to Drug Discovery and Biologics Jul 15, 2025

Wockhardt Projects Profitability Growth, Targets 18-20% Margins Jul 14, 2025

Wockhardt Ltd Exits US Generics Business, Focuses on Antibiotics and Biologics Jul 14, 2025

Wockhardt Announces Major Strategic Shift: Exits US Generics to Focus on Innovation Jul 11, 2025

More news about Wockhardt

01Jul 25

Wockhardt Unveils Zaynich Initiative for Global Licensing Agreements

Wockhardt, a prominent pharmaceutical company, has introduced the Zaynich Initiative, aimed at establishing worldwide licensing agreements. This strategic move is designed to expand Wockhardt's global footprint and potentially enhance its market presence. While specific details are limited, the initiative could lead to expanded market reach, revenue diversification, collaborative opportunities, and technology transfer. The pharmaceutical industry is closely watching the development of this initiative and its potential impact on Wockhardt's business strategy and market position.

06Jun 25

Wockhardt's Novel Antibiotic Zaynich Eyes $7 Billion Market Opportunity in US and Europe

Wockhardt Limited has announced that its novel antibiotic, Zaynich, has an addressable market opportunity of $7.00 billion in the United States and Europe. This potential revenue stream highlights the growing demand for innovative antibiotics in developed healthcare markets. The company's focus on this new drug demonstrates its strategic approach to addressing unmet medical needs and competing in high-value pharmaceutical segments. The success of Zaynich could have significant implications for both Wockhardt's growth and global public health efforts in combating antibiotic resistance.

29May 25

Wockhardt Narrows Q4 Loss, Reports 6% Revenue Growth

Wockhardt reported a consolidated net loss of ₹45.00 crore in Q4, significantly lower than the ₹177.00 crore loss in the same quarter last year. Revenue increased by 6% to ₹743.00 crore from ₹701.00 crore. The company's EBITDA turned positive at ₹64.00 crore, indicating improved operational performance. Akhilesh Krishna Gupta was reappointed as an Independent Director for a second five-year term.

08Apr 25

Wockhardt Expands European Presence with New Irish Subsidiary

Wockhardt Ltd's subsidiary, Wockhardt Bio AG, has incorporated a new wholly owned subsidiary in Ireland named Wockhardt Antibiotics (Ireland) Limited. The new entity, established on April 7, 2025, with an initial capital of 100 Euro, aims to strengthen Wockhardt's presence in the European market by channeling antibiotic products across the EU. This strategic move is expected to enhance the company's distribution network and leverage Ireland's favorable business environment as a gateway to Europe.

07Apr 25

Wockhardt to Exit US Generics Business Amid Market Challenges

Wockhardt, a major pharmaceutical company, has decided to exit its US generics business, marking a significant change in its operations. This move comes amid increasing competition and regulatory pressures in the US market. The decision suggests a reassessment of Wockhardt's global strategy and potential reallocation of resources to more profitable segments. The exit may create opportunities for other players in the US generics sector while raising questions about the challenges faced by international pharmaceutical companies in this market.